Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Immunome EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Immunome's EPS for the twelve months ending Mar 31, 2026 was -$2.37. For fiscal 2025 it was -$2.43. The highest annual figure on record is -$2.14 in fiscal 2021.

Annual eps

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$2.43	–
FY2024	Dec 31, 2024	-$5.00	–
FY2023	Dec 31, 2023	-$5.38	–
FY2022	Dec 31, 2022	-$3.09	–
FY2021	Dec 31, 2021	-$2.14	–
FY2020	Dec 31, 2020	-$5.26	–
FY2019	Dec 31, 2019	-$9.55	–

Quarterly eps

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2026	Mar 31, 2026	-$0.48	–
Q4 FY2025	Dec 31, 2025	-$0.74	–
Q3 FY2025	Sep 30, 2025	-$0.65	–
Q2 FY2025	Jun 30, 2025	-$0.50	–
Q1 FY2025	Mar 31, 2025	-$0.52	–
Q4 FY2024	Dec 31, 2024	-$1.28	–
Q3 FY2024	Sep 30, 2024	-$0.78	–
Q2 FY2024	Jun 30, 2024	-$0.60	–
Q1 FY2024	Mar 31, 2024	-$2.51	–
Q3 FY2023	Sep 30, 2023	-$0.36	–
Q2 FY2023	Jun 30, 2023	-$0.46	–
Q1 FY2023	Mar 31, 2023	-$0.35	–
Q4 FY2022	Dec 31, 2022	-$0.64	–
Q3 FY2022	Sep 30, 2022	-$0.75	–
Q2 FY2022	Jun 30, 2022	-$0.74	–
Q1 FY2022	Mar 31, 2022	-$0.96	–
Q4 FY2021	Dec 31, 2021	-$0.65	–
Q3 FY2021	Sep 30, 2021	-$0.65	–
Q2 FY2021	Jun 30, 2021	-$0.46	–
Q1 FY2021	Mar 31, 2021	-$0.37	–
Q3 FY2020	Sep 30, 2020	-$7.52	–
Q2 FY2020	Jun 30, 2020	-$2.45	–
Q1 FY2020	Mar 31, 2020	-$2.44	–
Q4 FY2019	Dec 31, 2019	-$2.66	–
Q3 FY2019	Sep 30, 2019	-$2.50	–